NCT05058118View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD)

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 8, 2019

Primary Completion Date

June 3, 2020

Study Completion Date

June 3, 2020

Conditions
Healthy
Interventions
DRUG

FL058

50mg、250mg、500mg、1000mg、1500mg、2000mg

DRUG

Placebo

empty bottle

Trial Locations (1)

Unknown

Huashan Hospital affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT05058118 - Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD) | Biotech Hunter | Biotech Hunter